SIGA Technologies, Inc.
SIGAHealthcare|Drug Manufacturers - Specialty & Generic|US
$3.10
+0.13 (+4.38%)
DCF Value
$8.71
Tangible Book / Share
$2.29
Cash / Share
$1.64
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04957485 Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS | Smallpox | P2 | Active | 100 | RCT, Double-blind | Tecovirimat, Smallpox and Mpox Vaccine |
| NCT04485039 Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders | Smallpox | P4 | Completed | 44 | RCT, Open-label | Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet |
| NCT04392739 Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG | Smallpox | P4 | Completed | 34 | Open-label | Tpoxx |
| NCT02474589 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat | Smallpox | P3 | Completed | 449 | RCT, Double-blind | tecovirimat |
| NCT05534984 Study of Tecovirimat for Human Mpox Virus | MPOX | P3 | Terminated | 719 | RCT, Double-blind | Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label) |
| NCT04971109 Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days | Smallpox | P3 | Completed | 467 | RCT, Double-blind | TPOXX |
| NCT00907803 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 | Orthopoxviral Disease | P2 | Completed | 107 | RCT, Double-blind | ST-246 400 mg, ST-246 600 mg, Placebo |
| NCT00431951 Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Healthy | P1 | Completed | 30 | RCT, Double-blind | ST-246, Placebo |
| NCT00728689 Phase I Trial of an Investigational Small Pox Medication | Orthopoxviral Disease, Smallpox | P1 | Completed | 12 | RCT, Double-blind | ST-246 Days 1 - 3, ST-246 Days 11 - 13 |
| NCT05380752 Tecovirimat Intravenous Treatment for Orthopox Virus Exposure | Orthopox Virus Infection | NO_LONGER_AVAILABLE | — | — | TPOXX IV (Tecovirimat Injection, 10 mg/mL) | |
| NCT03972111 A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox | Smallpox | Withdrawn | — | — | TPOXX 200Mg Capsule |